Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
123.64 USD   -0.55%
09/23INSIDER SELL : Moderna
MT
09/23Healthcare Shares Slip But Perform Better Than Broader Market -- Healthcare Roundup
DJ
09/23U.S. rollout of new COVID boosters off to slow start
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna - Evidation Enables First of Its Kind Moderna Study to Track COVID Vaccine Response in Real Life

08/17/2022 | 08:43am EDT

SAN MATEO, Calif. - Moderna recently conducted a digitally enabled, at-home study examining COVID-19 antibody response over time, made possible by Evidation. A preprint published on MedRxiv, Antibody Response Following COVID-19 Boosters During the Omicron Wave in the United States: A Decentralized, Digital Health, Real-World Study, reports individuals who received Moderna primary shots and boosters had more durable antibody levels than those who received Pfizer. This observational study is believed to be the first study worldwide to use decentralized procedures to assess real-world immunity following COVID-19 vaccination.

'Our goal is to uncover useful, longitudinal insights that enable researchers and public officials to apply real-world learnings faster. This study was designed and implemented in just three months and fully enrolled two weeks after launch, demonstrating the power of the Moderna Community built within Evidation's population,' said Christine Lemke, co-CEO and co-founder at Evidation.

For this study, 844 participants were recruited and enrolled for the study from the Moderna Community on Evidation, a community of over 100,000 people across the country launched earlier this year. The study included two vaccination cohorts: 1) individuals who had received two Moderna-only primary shots and a Moderna booster, and 2) individuals who had received two Pfizer-only primary shots and a Pfizer booster.

Participants collected three monthly blood samples using an at-home blood draw device, and sent the samples for lab-based antibody measurement. Results showed that participants who received Moderna vaccines had stable antibody levels for 20 weeks following the booster shot, compared to eight weeks for those receiving the Pfizer vaccine.

The study supports the finding that the Moderna-only COVID-19 vaccine series substantially boosts and maintains high antibody titers over time against the ancestral strain and variants of concern, including BA.1, suggesting that priming and boosting with this vaccine may be highly protective against COVID-19.

About Evidation

Evidation creates new ways to measure and improve health in everyday life. Built upon a foundation of user privacy and control over permissioned health data, Evidation's consumer platform is trusted by millions of individuals-generating data with unprecedented speed, scale, and rigor. We partner with leading healthcare companies to understand health and disease outside the clinic walls. Evidation is working to bring people individualized, proactive, and accessible healthcare-faster. Founded in 2012, Evidation is headquartered in California with employees working around the globe.

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -0.55% 123.64 Delayed Quote.-51.32%
PFIZER, INC. -1.10% 44.08 Delayed Quote.-25.35%
All news about MODERNA, INC.
09/23INSIDER SELL : Moderna
MT
09/23Healthcare Shares Slip But Perform Better Than Broader Market -- Healthcare Roundup
DJ
09/23U.S. rollout of new COVID boosters off to slow start
RE
09/23Over 4 million Americans administered updated COVID boosters, says CDC
RE
09/22Carisma and Sesen Bio Combine, Raise $30M for CAR-M Therapeutics
AQ
09/21U.S. CDC expects Omicron COVID boosters for kids by mid-October
RE
09/21MODERNA EXEC : 'eager' to collaborate with China on supplying COVID vaccines
RE
09/21Catalent Continues Production Of Moderna's COVID-19 Jab In US Site Despite Factory Issu..
MT
09/20U.S. delivers over 25 million COVID boosters; Moderna's shot in limited supply
RE
09/20France clears Omicron-adapted COVID boosters for autumn vaccination drive
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 21 889 M - -
Net income 2022 10 978 M - -
Net cash 2022 15 984 M - -
P/E ratio 2022 4,70x
Yield 2022 -
Capitalization 48 368 M 48 368 M -
EV / Sales 2022 1,48x
EV / Sales 2023 2,80x
Nbr of Employees 2 700
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 123,64 $
Average target price 214,75 $
Spread / Average Target 73,7%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-51.32%48 368
IQVIA HOLDINGS INC.-32.86%35 330
LONZA GROUP AG-41.68%33 599
SEAGEN INC.-9.96%25 673
ALNYLAM PHARMACEUTICALS, INC.19.54%24 099
CELLTRION, INC.-15.40%16 277